The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment.

AbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing ...

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

PhRMA said in a January submission to the US trade review that US companies were the “constant target of compulsory licensing ...